NCT01421134

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 211 (actual)
• Sponsor: Sumitomo Pharma America, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.

Conditions

• Major Depressive Disorder With Mixed Features

Interventions

Type	Name	Description
DRUG	Lurasidone	20, 40, 60 mg, flexible dose, once daily PM 6 weeks
DRUG	Placebo	Placebo

Timeline

• Start date: 2011-09-01
• Primary completion: 2014-10-01
• Completion: 2014-10-01
• First posted: 2011-08-22
• Last updated: 2016-07-15
• Results posted: 2015-10-09

Locations

43 sites across 5 countries: United States, Russia, Serbia, Ukraine, United Kingdom